JSM 2014 Home
Online Program Home
My Program

Legend: Boston Convention & Exhibition Center = CC, Westin Boston Waterfront = W, Seaport Boston Hotel = S
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.

Activity Details

330 * Tue, 8/5/2014, 10:30 AM - 12:20 PM CC-156C
Advancing Oncology Drug Development Using Biomarker and Surrogate Endpoints — Topic Contributed Papers
Biopharmaceutical Section
Organizer(s): Rong (Rachel) Chu, Agensys
Chair(s): Rong (Rachel) Chu, Agensys   
10:35 AM Pitfalls in the Use of Progression-Free Survival as a Surrogate for Overall Survival in Cancer Clinical Trials Gregory Pond, McMaster University
10:55 AM Practical Enhancements to the Adaptive Signature Type of Design Jonathan Denne, Eli Lilly and Company ; Adarsh Joshi, Gilead ; Lei Shen, Eli Lilly and Company ; Peigang Li, Eli Lilly and Company ; Hollins Showalter, Eli Lilly and Company ; Eric Nantz, Eli Lilly and Company
11:15 AM The Application of Group Sequential Stopping Boundaries to Evaluate the Treatment Effect of an Experimental Agent Across a Range of Marker Expression Eric Holmgren, Oncomed
11:35 AM Designing Clinical Studies of Targeted Drugs Across Cancer Modalities — William Barry, Dana-Farber Cancer Institute ; Lorenzo Trippa, Harvard School of Public Health
11:55 AM Discussant: Alan Hartford, Agensys
12:15 PM Floor Discussion

2014 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Professional Development program, please contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

ASA Meetings Department  •  732 North Washington Street, Alexandria, VA 22314  •  (703) 684-1221  •  meetings@amstat.org
Copyright © American Statistical Association.